Intrahepatic epidoxorubicin in metastatic and primary liver tumours: a phase II study.
Primary and metastatic gastrointestinal tumours in the liver have been treated by intrahepatic artery infusion of chemotherapeutic drugs in an attempt to increase the efficacy of the administered agents. Among the several active agents, 4' epidoxorubicin, an anthracycline analogue, was selected for this study because of the therapeutic level reached in the liver by this drug. Seven patients with primary hepatic carcinoma and twenty with metastatic adenocarcinoma of the colon to the liver received intraarterial hepatic infusion of epidoxorubicin at the dosage of 30 mg weekly. No haematological or gastrointestinal grade 3-4 toxicity was recorded, only one patient experienced transient cardiac toxicity. No objective response was observed in primary hepatic carcinoma and six objective responses, 1 complete and 5 partial (30%), were achieved in metastatic colorectal cancer patients. This results is not far from those reported with FUDR, but does not justify epidoxorubicin in colorectal cancer patients as first line intraarterial treatment.
Nobile
M T
MT
Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy.
Vidili
M G
MG
Sertoli
M R
MR
Venturini
M
M
Simoni
G
G
Civalleri
D
D
Bertoglio
S
S
Percivale
P
P
Torelli
P
P
Spagliardi
E
E
D001772:Blood Cell Count; D003110:Colonic Neoplasms / Q000188:drug therapy*; D004341:Drug Evaluation; D015251:Epirubicin / Q000008:administration & dosage / Q000627:therapeutic use / Q000633:toxicity*; D005260:Female; D006499:Hepatic Artery; D006801:Humans; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D008875:Middle Aged
D015251:Epirubicin